» Authors » C John Sperati

C John Sperati

Explore the profile of C John Sperati including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 65
Citations 704
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Ghag R, Kaushal M, Nwanne G, Knoten A, Kiryluk K, Rosenberg A, et al.
bioRxiv . 2023 Nov; PMID: 37986991
Translational Statement: The manuscript describes innovation, application and discovery that impact clinical care in kidney disease. First, the approach to maximize use of remnant frozen clinical biopsies to inform on...
12.
Kim J, Zhang C, Sperati C, Barman I, Bagnasco S
J Histochem Cytochem . 2023 Oct; 71(11):643-652. PMID: 37833851
In the clinical setting, routine identification of the main types of tissue amyloid deposits, light-chain amyloid (AL) and serum amyloid A (AA), is based on histochemical staining; rarer types of...
13.
Menez S, Coca S, Moledina D, Wen Y, Chan L, Thiessen-Philbrook H, et al.
Am J Kidney Dis . 2023 Jun; 82(3):322-332.e1. PMID: 37263570
Rationale & Objective: Patients hospitalized with COVID-19 are at increased risk for major adverse kidney events (MAKE). We sought to identify plasma biomarkers predictive of MAKE in patients hospitalized with...
14.
Cervantes C, Bloch E, Sperati C
Am J Kidney Dis . 2023 Feb; 81(4):475-492. PMID: 36775691
From producing individual blood components for transfusion to the removal of pathogenic substances, apheresis is a cornerstone of modern medical therapies. The use of therapeutic plasma exchange (TPE), in which...
15.
Kallash M, Wang Y, Smith A, Trachtman H, Gbadegesin R, Nester C, et al.
Clin J Am Soc Nephrol . 2023 Feb; 18(3):344-355. PMID: 36763813
Background: FSGS is a heterogeneous diagnosis with a guarded prognosis. Polymorphisms in the apolipoprotein L1 ( APOL1 ) gene are associated with developing FSGS and faster progression to kidney failure...
16.
Chen D, Helmuth M, Smith A, Canetta P, Ayoub I, Mucha K, et al.
Am J Kidney Dis . 2023 Jan; 81(6):695-706.e1. PMID: 36608921
Rationale & Objective: Adolescent- and adult-onset minimal change disease (MCD) may have a clinical course distinct from childhood-onset disease. We characterized the course of children and adults with MCD in...
17.
Nester C, Appel G, Bomback A, Bouman K, Cook H, Daina E, et al.
Am J Nephrol . 2022 Nov; 53(10):687-700. PMID: 36423588
Introduction: C3 glomerulopathy (C3G) is an ultrarare, chronic and progressive nephropathy mediated by dysregulation of the alternative pathway of complement (AP), with poor prognosis and limited treatment options. Targeted inhibition...
18.
Podos S, Trachtman H, Appel G, Bomback A, Dixon B, Wetzels J, et al.
Am J Nephrol . 2022 Nov; 53(10):675-686. PMID: 36404708
Introduction: C3 glomerulopathy (C3G) is a rare, progressive kidney disease resulting from dysregulation of the alternative pathway (AP) of complement. Biomarkers at baseline were investigated in patients with C3G who...
19.
Krissberg J, OShaughnessy M, Smith A, Helmuth M, Almaani S, Aviles D, et al.
Am J Kidney Dis . 2022 Oct; 81(3):318-328.e1. PMID: 36191724
Rationale & Objective: The effects of race, ethnicity, socioeconomic status (SES), and disease severity on acute care utilization in patients with glomerular disease are unknown. Study Design: Prospective cohort study....
20.
Cervantes C, Sperati C
Kidney360 . 2022 Apr; 2(9):1399-1401. PMID: 35373111
No abstract available.